◆英語タイトル:BioTime Inc (BTX) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C2854
◆発行会社(調査会社):
GlobalData
◆発行日:2018年8月
◆ページ数:54
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
BioTime Inc (BTX) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
BioTime Inc (BioTime) is a biotechnology company which focuses on regenerative medicine and plasma volume expanders. The company’s Hextend is a blood plasma volume expander used for the treatment of hypovolemia in surgery, emergency trauma treatment, and other applications. It is also developing Renevia facial aesthetics product, a potential treatment for facial lipoatrophy; AST-VAC1 and AST-VAC2 autologous (patient-specific) cancer vaccines; Premvia for tendon and wound-management applications; OpRegen for the treatment of dry form of age-related macular degeneration (AMD); AST-OPC1 for spinal cord injury rehabilitation; HyStem hydrogel products; and mobile health software products. BioTime’s products can be used in oncology, neuroscience, orthopedics and blood and vascular diseases. Its products are developed on its pluripotent stem technology. The company has operations in the US, Hong Kong, Israel and Singapore. BioTime is headquartered in California, the US.
BioTime Inc Key Recent Developments
Aug 02,2018: BioTime reports second quarter results and recent corporate accomplishments-2018
Aug 02,2018: BioTime reports second quarter results and recent corporate accomplishments for 2018
Jun 29,2018: BioTime Awarded Grant from the National Institutes of Health
Jun 29,2018: BioTime Awarded Grant From the NIH (National Institutes of Health)
Jun 05,2018: AgeX Therapeutics Appoints John F. Mauldin to Board of Directors
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 – About the Company 6
BioTime Inc – Key Facts 6
BioTime Inc – Key Employees 7
BioTime Inc – Key Employee Biographies 8
BioTime Inc – Major Products and Services 9
BioTime Inc – History 10
BioTime Inc – Company Statement 14
BioTime Inc – Locations And Subsidiaries 15
Head Office 15
Other Locations & Subsidiaries 15
Joint Venture 16
Section 2 – Company Analysis 17
Company Overview 17
BioTime Inc – Business Description 18
BioTime Inc – SWOT Analysis 19
SWOT Analysis – Overview 19
BioTime Inc – Strengths 19
BioTime Inc – Weaknesses 20
BioTime Inc – Opportunities 21
BioTime Inc – Threats 22
BioTime Inc – Key Competitors 23
Section 3 – Company Financial Ratios 24
Financial Ratios – Capital Market Ratios 24
Financial Ratios – Annual Ratios 25
Performance Chart 28
Financial Performance 28
Financial Ratios – Interim Ratios 29
Financial Ratios – Ratio Charts 30
Section 4 – Company’s Lifesciences Financial Deals and Alliances 31
BioTime Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 31
BioTime Inc, Medical Equipment, Deals By Type, 2012 to YTD 2018 32
BioTime Inc, Recent Deals Summary 33
Section 5 – Company’s Recent Developments 34
Aug 14, 2018: Oncocyte reports second quarter 2018 financial results and positive corporate developments 34
Aug 02, 2018: BioTime reports second quarter results and recent corporate accomplishments-2018 36
Jun 05, 2018: AgeX Therapeutics Appoints John F. Mauldin to Board of Directors 38
May 15, 2018: OncoCyte Reports First Quarter 2018 Financial Results 39
May 10, 2018: BioTime Reports First Quarter Results and Recent Corporate Accomplishments 41
Apr 03, 2018: Leading Molecular Diagnostics Executive Ronnie Andrews Appointed to OncoCyte’s Board of Directors 43
Apr 02, 2018: OncoCyte Names Cavan Redmond Chairman of the Board of Directors 44
Apr 02, 2018: OncoCyte Files Patents for 190 Newly Identified Novel Lung Cancer Biomarkers 45
Apr 02, 2018: Oncocyte Reports Fourth Quarter and Full Year 2017 Financial Results 46
Mar 15, 2018: BioTime Reports Fourth Quarter and Fiscal 2017 Results 48
Section 6 – Appendix 50
Methodology 50
Ratio Definitions 50
About GlobalData 54
Contact Us 54
Disclaimer 54
List of Tables
BioTime Inc, Key Facts 6
BioTime Inc, Key Employees 7
BioTime Inc, Key Employee Biographies 8
BioTime Inc, Major Products and Services 9
BioTime Inc, History 10
BioTime Inc, Subsidiaries 15
BioTime Inc, Joint Venture 16
BioTime Inc, Key Competitors 23
BioTime Inc, Ratios based on current share price 24
BioTime Inc, Annual Ratios 25
BioTime Inc, Annual Ratios (Cont...1) 26
BioTime Inc, Annual Ratios (Cont...2) 27
BioTime Inc, Interim Ratios 29
BioTime Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 31
BioTime Inc, Medical Equipment, Deals By Type, 2012 to YTD 2018 32
BioTime Inc, Recent Deals Summary 33
Currency Codes 50
Capital Market Ratios 50
Equity Ratios 51
Profitability Ratios 51
Cost Ratios 52
Liquidity Ratios 52
Leverage Ratios 53
Efficiency Ratios 53
List of Figures
BioTime Inc, Performance Chart (2013 - 2017) 28
BioTime Inc, Ratio Charts 30
BioTime Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 31
BioTime Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 32